Behind the curtain on Lundbeck's Alder buy: A migraine team-up morphed into a full-on buyout

24th September 2019 Uncategorised 0

Alder BioPharmaceuticals had been looking for an ex-U.S. partner for its CGRP migraine drug eptinezumab. But Lundbeck, looking to expand in brain disease, developed an appetite for the whole company—and fought off other potential partners to eventually win a $2 billion buyout.

More: Behind the curtain on Lundbeck's Alder buy: A migraine team-up morphed into a full-on buyout
Source: fierce